Non-steroidal anti-inflammatory drugs are used to treat pain, high fever, and prevention of blood clots. Moreover, when high doses of non-steroidal anti-inflammatory drugs (NSAIDs) are administered, the inflammation is reduced. The non-steroidal drugs having depressing and anti-inflammatory action. Non-steroidal anti-inflammatory drugs (NSAIDs) works by inhibiting the COX-1 and COX-2 enzymes, which are responsible for inflammation. Paracetamol, ibuprofen, aspirin, and naproxen are common types of non-steroidal anti-inflammatory drugs.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that first emerged in late December in Hubei province of the Wuhan city in China. The virus that causes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly infectious and is transmitted from person to person. Since the outbreak in December 2019, the disease has spread to across 213 countries around the globe with the World Health Organization declaring it a pandemic on March 11, 2020.
Pharmaceutical and biotech companies along with governments around the globe are working to address the COVID-19 outbreak, from supporting the vaccines development to medicine supply chain planning. Approximately, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a significant increase in demand for the treatment of COVID-19. Such increased demand for these drugs has offered huge opportunities for manufacturers of COVID-19 treatment drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future due to the demand for vaccine and the treatment drugs for COVID-19. This in anticipated to have a significant impact on the non-steroidal anti-Inflammatory drugs (NSAIDs) market.
Top Impacting Factors
- Rise in chronic pain cases, the surge in inflammation cases, preference of non-steroidal anti-inflammatory drugs (NSAIDs) over the opioids, increase in geriatric population, rise in awareness about the use of non-steroidal anti-inflammatory drugs (NSAIDs) and constant increase in business strategies are factors that drive the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.
- Furthermore, increase in non-steroidal anti-inflammatory drugs (NSAIDs) adoption, advantages and effectiveness using non-steroidal anti-inflammatory drugs (NSAIDs), low cost of treatment, rise in demand for non-steroidal anti-inflammatory drugs (NSAIDs), emerging technology in developing countries, research and development activities, and launch of novel drugs are the key factors that boost the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.
- However, side effects associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as dizziness, nausea, and allergic reactions can limit the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.
- Quick authority approvals by the governments and increase in government initiatives raised awareness and funding in this market are anticipated to provide lucrative opportunities for the expansion of the market.
Market Trend
New R & D Activities to Develop Novel NSAID Products
The U.S. Food and Drug Administration (USFDA) approved over-the-counter diclofenac sodium skin gel 1% of Perrigo Company plc in May 2019. This product provides chronic pain relief.
Teva Pharmaceutical Industries Ltd. announced the launch of Flector 1 Patch in March 2019. The product was released in the U.S. market. It is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat chronic pain caused by minor wounds, injuries, and strains
Key Benefits of the Report
- This study presents the analytical depiction of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market share.
- The current market is quantitatively analyzed to highlight the growth scenario of the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market analysis based on competitive intensity and the that competition will take shape in coming years
Questions answered in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report
- Who are the leading market players active in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market?
- What current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the future projections that would help in taking further strategic steps?
- What is "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)"?
- What is the prediction of the "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)" Market in the future?
- Who are the leading global players in the "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)" Market?
- What are the current and predicted trends?
- What are the key benefits of the "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)" Market report?
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report Highlights
| Aspects | Details |
 By Disease Indication |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Endo, Eli Lilly, Merck, Grunenthal, GSK plc, Johnson and Johnson Services, Inc., Yunnan Baiyao, AstraZeneca, Teva, Allergan, Depomed, Purdue, Bayer AG, Sanofi, Pfizer Inc. |
Loading Table Of Content...
